207 related articles for article (PubMed ID: 35214121)
1. Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview.
Slapak EJ; El Mandili M; Bijlsma MF; Spek CA
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214121
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer.
Slapak EJ; El Mandili M; Brink MST; Kros A; Bijlsma MF; Spek CA
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445886
[TBL] [Abstract][Full Text] [Related]
3. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer.
Slapak EJ; El Mandili M; Ten Brink MS; Kros A; Bijlsma MF; Spek CA
Cancer Lett; 2024 May; 590():216845. PubMed ID: 38589004
[TBL] [Abstract][Full Text] [Related]
4. ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer.
Slapak EJ; Kong L; El Mandili M; Nieuwland R; Kros A; Bijlsma MF; Spek CA
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282781
[TBL] [Abstract][Full Text] [Related]
5. Meta-Analysis of Efficacy of Chemotherapy Delivered by Mesoporous Silica Nanoparticles to Tumor-Bearing Mice.
McGoron A
Crit Rev Biomed Eng; 2020; 48(6):327-418. PubMed ID: 33641279
[TBL] [Abstract][Full Text] [Related]
6. A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies.
Gao Y; Gao D; Shen J; Wang Q
Front Chem; 2020; 8():598722. PubMed ID: 33330389
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer.
Tarannum M; Holtzman K; Dréau D; Mukherjee P; Vivero-Escoto JL
J Control Release; 2022 Jul; 347():425-434. PubMed ID: 35569588
[TBL] [Abstract][Full Text] [Related]
8. Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer.
Li T; Shi S; Goel S; Shen X; Xie X; Chen Z; Zhang H; Li S; Qin X; Yang H; Wu C; Liu Y
Acta Biomater; 2019 Apr; 89():1-13. PubMed ID: 30797106
[TBL] [Abstract][Full Text] [Related]
9. Matrix Metalloproteinase-Responsive Mesoporous Silica Nanoparticles Cloaked with Cleavable Protein for "Self-Actuating" On-Demand Controlled Drug Delivery for Cancer Therapy.
Vaghasiya K; Ray E; Sharma A; Katare OP; Verma RK
ACS Appl Bio Mater; 2020 Aug; 3(8):4987-4999. PubMed ID: 35021676
[TBL] [Abstract][Full Text] [Related]
10. Smart Mesoporous Silica Nanoparticles for Protein Delivery.
Liu HJ; Xu P
Nanomaterials (Basel); 2019 Apr; 9(4):. PubMed ID: 30986952
[TBL] [Abstract][Full Text] [Related]
11. Carboxyl-functionalized mesoporous silica nanoparticles for the controlled delivery of poorly water-soluble non-steroidal anti-inflammatory drugs.
Gou K; Wang Y; Guo X; Wang Y; Bian Y; Zhao H; Guo Y; Pang Y; Xie L; Li S; Li H
Acta Biomater; 2021 Oct; 134():576-592. PubMed ID: 34280558
[TBL] [Abstract][Full Text] [Related]
12. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery.
Tang F; Li L; Chen D
Adv Mater; 2012 Mar; 24(12):1504-34. PubMed ID: 22378538
[TBL] [Abstract][Full Text] [Related]
13. An optimized mesoporous silica nanosphere-based carrier system with chemically removable Au nanoparticle caps for redox-stimulated and targeted drug delivery.
Zhang L; Wei F; Al-Ammari A; Sun D
Nanotechnology; 2020 Nov; 31(47):475102. PubMed ID: 32413886
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment.
Shakeran Z; Keyhanfar M; Varshosaz J; Sutherland DS
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111526. PubMed ID: 33255079
[TBL] [Abstract][Full Text] [Related]
15. Applications and Biocompatibility of Mesoporous Silica Nanocarriers in the Field of Medicine.
Zhang C; Xie H; Zhang Z; Wen B; Cao H; Bai Y; Che Q; Guo J; Su Z
Front Pharmacol; 2022; 13():829796. PubMed ID: 35153797
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles.
Cheng YJ; Luo GF; Zhu JY; Xu XD; Zeng X; Cheng DB; Li YM; Wu Y; Zhang XZ; Zhuo RX; He F
ACS Appl Mater Interfaces; 2015 May; 7(17):9078-87. PubMed ID: 25893819
[TBL] [Abstract][Full Text] [Related]
17. YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
Liu Z; Tao Z; Zhang Q; Wan S; Zhang F; Zhang Y; Wu G; Wang J
Cancer Chemother Pharmacol; 2018 Apr; 81(4):687-695. PubMed ID: 29392452
[TBL] [Abstract][Full Text] [Related]
18. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
19. Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery.
Li Z; Zhang Y; Feng N
Expert Opin Drug Deliv; 2019 Mar; 16(3):219-237. PubMed ID: 30686075
[TBL] [Abstract][Full Text] [Related]
20. Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect.
Frickenstein AN; Hagood JM; Britten CN; Abbott BS; McNally MW; Vopat CA; Patterson EG; MacCuaig WM; Jain A; Walters KB; McNally LR
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33920503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
